-
1.发明授权Methods using recombinant anti-epidermal growth factor receptor antibody compositions 有权使用重组抗表皮生长因子受体抗体组合物的方法公开(公告)号：US08663640B2
公开(公告)日：2014-03-04
申请号：US13061417
申请日：2009-08-27
IPC分类号： A61K39/395 , C07K16/30
CPC分类号： C07K16/2863 , A61K2039/507 , C07K14/71 , C07K2317/24 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/569 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92
摘要： The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides the use of an antibody composition with two distinct non-overlapping binding specificities to human EGFR. The antibody composition is effecting in treating cancer following treatment with other anti-EGFR antibodies, whether the cancer shows progression during or following the prior treatment or not. The antibody composition can also be used for repeated treatment of recurrent tumors following first-line therapy with the antibody composition of the invention, as the composition does not lead to selection of resistant tumors. A further therapeutic use is the use of an antibody composition of the invention for treatment of cancer that is resistant to known anti-EGFR antibodies.
摘要翻译： 本发明涉及用于人类癌症治疗的重组抗体领域。 更具体地，本发明提供了对人EGFR具有两种不同的非重叠结合特异性的抗体组合物的用途。 抗体组合物在用其他抗EGFR抗体治疗后，无论癌症是否在先前治疗期间或之后显示进展，都在治疗癌症中。 在本发明的抗体组合物一线治疗后，抗体组合物也可用于重复治疗复发性肿瘤，因为该组合物不导致抗性肿瘤的选择。 进一步的治疗用途是使用本发明的抗体组合物治疗对已知抗EGFR抗体具有抗性的癌症。
-
公开(公告)号：US20110229463A1
公开(公告)日：2011-09-22
申请号：US13061417
申请日：2009-08-27
IPC分类号： A61K39/395 , C07K16/32 , C12N5/09 , A61P35/00
CPC分类号： C07K16/2863 , A61K2039/507 , C07K14/71 , C07K2317/24 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/569 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92
摘要： The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides the use of an antibody composition with two distinct non-overlapping binding specificities to human EGFR. The antibody composition is effecting in treating cancer following treatment with other anti-EGFR antibodies, whether the cancer shows progression during or following the prior treatment or not. The antibody composition can also be used for repeated treatment of recurrent tumours following first-line therapy with the antibody composition of the invention, as the composition does not lead to selection of resistant tumours. A further therapeutic use is the use of an antibody composition of the invention for treatment of cancer that is resistant to known anti-EGFR antibodies.
摘要翻译： 本发明涉及用于人类癌症治疗的重组抗体领域。 更具体地，本发明提供了对人EGFR具有两种不同的非重叠结合特异性的抗体组合物的用途。 抗体组合物在用其他抗EGFR抗体治疗后，无论癌症是否在先前治疗期间或之后显示进展，都在治疗癌症中。 在本发明的抗体组合物一线治疗后，抗体组合物也可用于重复治疗复发性肿瘤，因为该组合物不导致抗性肿瘤的选择。 进一步的治疗用途是使用本发明的抗体组合物治疗对已知抗EGFR抗体具有抗性的癌症。
-
搜索结果
2 条记录 (耗时 0.023 秒)
